Sinusitis News and Research

Latest Sinusitis News and Research

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted and filed the company's supplemental Biologics License Application for subcutaneous use of Xolair (omalizumab) in people with Chronic Idiopathic Urticaria who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses.

11 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Respiratory infection antibiotic guidance often ignored

Researchers from the USA say that more must be done to improve adherence to guidelines for antibiotic prescriptions for upper respiratory tract infections, sinusitis, and pharyngitis.

2 Sep 2013

FDA approves Galderma's Mirvaso topical gel for facial erythema of rosacea

Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.

27 Aug 2013

Otolaryngologists to present newest specialty research in OTO EXPO

The 2013 Annual Meeting & OTO EXPOSM of the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 29 - October 2, at the Vancouver Convention Centre in Vancouver, BC, Canada.

17 Aug 2013

Educating pediatricians on appropriate antibiotic usage can improve outcomes in children’s infections

As disease-causing microbes continue their worrisome trend of developing resistance to commonly used antibiotics, public health experts have called for more selective use of those medicines. A new study suggests that educating pediatricians in their offices, and auditing their prescription patterns, encourages them to choose more appropriate antibiotics for children with common respiratory infections.

14 Jun 2013

Study: Intervention improves adherence to prescribing guidelines for pediatric bacterial ARTIs

An intervention consisting of clinician education coupled with personalized audit and feedback about antibiotic prescribing improved adherence to prescribing guidelines for common pediatric bacterial acute respiratory tract infections, although the intervention did not affect antibiotic prescribing for viral infections, according to a study in the June 12 issue of JAMA.

14 Jun 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).

18 Apr 2013

Salivary duct access products launched by Cook Medical to offer minimally invasive options for obstructive salivary gland disease

Cook Medical has launched a suite of salivary duct access products that offer minimally invasive options for the treatment of obstructive salivary gland disease. Minimally invasive treatment of obstructive salivary gland disease can reduce the need for invasive open surgery.

18 Mar 2013

Otolaryngology, head and neck surgery: an interview with Thomas Cherry, Cook Medical

Cook Medical is the world’s largest privately held medical device manufacturer. The ENT division is Cook’s 10th business unit/clinical division and we are excited to meet the needs of ENT patients.

From COOK MEDICAL INC. 18 Feb 2013

Underestimating cough duration may skew antibiotic perceptions

US researchers suggest that one reason patients request antibiotics for respiratory infections is that they greatly underestimate how long it usually takes for acute cough illness to resolve.

17 Jan 2013

Antibiotic prescribing rates raise concerns over e-visits

E-visits offer a comparable standard of care to traditional physician office visits but antibiotic prescribing rates are higher, particularly for urinary tract infections, say US investigators.

23 Nov 2012

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL- (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012.

7 Nov 2012

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.

5 Oct 2012

‘Friendly bacteria’ may help prevent sinusitis

Having the right bacteria present in a person’s sinuses might be key to preventing chronic sinusitis, say researchers.

21 Sep 2012

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Acton Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the sNDA (Supplemental New Drug Application) for AEROSPAN (flunisolide HFA, 80 mcg) Inhalation Aerosol, a hydrofluoroalkane (HFA) orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in adult and pediatric patients 6 years of age and older.

21 Sep 2012

Bilateral pediatric sinusitis takes longer to heal after surgery

Children should be evaluated for an extended period after undergoing bilateral endoscopic sinus surgery, show findings from a retrospective study.

19 Sep 2012

Loss of normal microbial diversity may be culprit behind chronic sinusitis

A common bacteria ever-present on the human skin and previously considered harmless, may, in fact, be the culprit behind chronic sinusitis, a painful, recurring swelling of the sinuses that strikes more than one in ten Americans each year, according to a study by scientists at the University of California, San Francisco.

13 Sep 2012

Sinusitis News and Research

Latest Sinusitis News and Research

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Respiratory infection antibiotic guidance often ignored

FDA approves Galderma's Mirvaso topical gel for facial erythema of rosacea

Otolaryngologists to present newest specialty research in OTO EXPO

Educating pediatricians on appropriate antibiotic usage can improve outcomes in children’s infections

Study: Intervention improves adherence to prescribing guidelines for pediatric bacterial ARTIs

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

Salivary duct access products launched by Cook Medical to offer minimally invasive options for obstructive salivary gland disease

Otolaryngology, head and neck surgery: an interview with Thomas Cherry, Cook Medical

Underestimating cough duration may skew antibiotic perceptions

Antibiotic prescribing rates raise concerns over e-visits

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

‘Friendly bacteria’ may help prevent sinusitis

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Bilateral pediatric sinusitis takes longer to heal after surgery

Loss of normal microbial diversity may be culprit behind chronic sinusitis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Sinusitis News and Research

Latest Sinusitis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in